TherapeuticsMD (TXMD) to Release Earnings on Monday

TherapeuticsMD (NASDAQ:TXMD) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 18th. Analysts expect the company to announce earnings of ($6.1250) per share and revenue of $19.7680 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 4:00 PM ET.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $6.07. TherapeuticsMD had a negative net margin of 18.83% and a negative return on equity of 2.41%. The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $19.77 million.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD opened at $1.98 on Monday. TherapeuticsMD has a 1 year low of $0.98 and a 1 year high of $2.95. The company’s 50-day moving average is $2.15 and its 200 day moving average is $1.95. The stock has a market capitalization of $22.91 million, a P/E ratio of -198.00 and a beta of 0.58.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC boosted its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,273 shares of the company’s stock after purchasing an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. 30.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.